Jul. 15 at 7:24 PM
$VXRT Real vs Imagined (Part 2 of 2)
In my last post, I laid out the full prompt to ChatGPT 5.6 Pro. After 25 minutes of analysis, here is the unedited version of what it returned:
CHATGPT 5.6 PRO RESPONSE (unedited):
Bottom line
The public record fits a deliberately staged license-and-option structure far better than an imminent, secretly completed takeover. Sanofi already receives the COVID data it needs without acquiring Vaxart, while Vaxart retains norovirus, influenza, HPV and other non-coronavirus rights.
Important context: Vaxart had
$61 million of cash and investments at March 31, 2026, approximately 242 million basic shares, and projected runway into Q2 2027, although it acknowledged that additional capital will be needed and established a potential
$25 million equity line. The 5,085-participant main cohort is expected to read out in the first half of 2027. The 400-person sentinel cohort was encouraging for safety but was expressly not powered to determine comparative efficacy.
1. Likelihood that a Sanofi acquisition has already been secretly negotiated
My estimates:
* Signed definitive acquisition agreement being improperly withheld: under 1%
* Substantially negotiated but unsigned transaction awaiting final approvals: about 5%
* Some preliminary strategic discussions have occurred: perhaps 15–25%
A signed material merger agreement normally must be reported on Form 8-K within four business days. Confidential preliminary discussions, however, generally can remain undisclosed.
The chronology argues against a hidden deal. Sanofi first approached Dynavax about an acquisition on December 12, 2024—almost eleven months before Dynavax signed the Vaxart agreement. Sanofi’s stated rationale for buying Dynavax focused on marketed HEPLISAV-B and the shingles candidate, not Vaxart. The Vaxart license was likely reviewed during Sanofi’s later-stage diligence, but I found no public indication that it was a principal acquisition driver.
2. Buy now or wait?
For Sanofi, waiting is more rational. Sanofi inherited an exclusive worldwide coronavirus license, ongoing access to all Phase 2b data, technology-transfer rights and the ability—after the trial and FDA end-of-Phase-2 process—to take over development for an additional
$50 million. It can therefore let BARDA and Vaxart absorb much of the remaining clinical risk before committing substantially more capital.
Buying now would make sense only if Sanofi:
* assigns substantial value to the non-coronavirus platform and pipeline;
* fears a competitor will acquire norovirus, flu, avian-flu or platform rights; or
* believes Vaxart is materially undervalued even after including clinical and financing risk.
For Vaxart, waiting offers greater expected upside but also greater downside. Strong Phase 2b data and a credible norovirus partnership could transform the valuation. Conversely, disappointing data, delay, dilution or an unfavorable regulatory path could reduce it substantially. A sale today would be more sensible if structured with a meaningful upfront premium plus contingent-value rights tied to Phase 2b, Sanofi’s election and norovirus milestones.
A competing buyer could acquire Vaxart while Sanofi’s coronavirus rights remained in place. The filed agreement expressly anticipates a Vaxart change of control and establishes IP carve-outs and information firewalls, although portions of the assignment provisions are redacted.
My base case: wait for additional de-risking, or pursue another asset-level partnership, rather than a whole-company acquisition now.
3. Fred Hutch data and possible sharing with Sanofi
Yes, data could be generated and analyzed before completion of the full Phase 2b trial. But the
$17 million Fred Hutch award is not a separate small Vaxart clinical trial. It is a BARDA-funded statistical and immune-correlate program covering multiple Project NextGen modalities, specifically including oral-pill and nasal-spray vaccine trials. Biomarker samples and immune-response data can arise well before final 12-month database lock.
I found no public evidence of a special Fred Hutch-to-Sanofi information channel. That is largely beside the point, however, because the Vaxart agreement independently requires Vaxart to provide Sanofi/Dynavax with all Phase 2b data—including sentinel, safety, topline and final data—promptly after it first becomes available.
Confidential data sharing with Sanofi ordinarily would not automatically require public disclosure, provided Sanofi is bound by confidentiality. Regulation FD recognizes confidential disclosures; insider-trading restrictions still apply. A signed material acquisition agreement would be reportable, but ordinary clinical-data exchange or confidential preliminary negotiations generally would not by itself trigger an immediate announcement.
4. Most likely acquisition timeline
Interpreting “Summer” as through August 31, 2026, and “acquisition” as a whole-company acquisition by Sanofi or another buyer:
Period Probability
Summer 2026 3%
September 1–December 31, 2026 7%
2027 30%
2028 15%
None by the end of 2028 45%
These are judgment estimates, not statistical forecasts. 2027 is the most logical window conditional on a transaction occurring, because the main Phase 2b results, regulatory interaction and Sanofi election process should clarify both platform value and COVID economics. The “none” category is largest because an expanded license, norovirus partnership, financing or continued independence may be more economical than buying the entire company.
5. Possible acquisition price
Using your
$0.55 price and approximately 242 million basic shares, Vaxart’s basic equity value is roughly
$133 million.
My estimated headline ranges are:
* Acquisition today:
$1.50–
$3.00 per share, with approximately
$2.25 as a central estimate.
* Exceptional auction or substantial contingent-value rights today: possibly
$4–
$5.
* After strong, statistically persuasive Phase 2b results plus a credible norovirus partnership:
$4–
$8, with approximately
$6 as a central estimate.
* Exceptional post-data outcome with several serious bidders: perhaps
$10–
$12.
The positive case includes the differentiated oral platform, large BARDA-sponsored trial, existing human influenza and norovirus evidence, second-generation norovirus immune responses and avian-influenza optionality. The negative case is that Vaxart has no approved vaccine; COVID efficacy remains unproven; the norovirus acute-gastroenteritis reduction was not statistically significant; FDA requested additional clinical data regarding the proposed norovirus correlate; and important original U.S. platform patents expire in 2027, although other formulation, norovirus and pending COVID patent families extend much longer. BARDA’s approximately
$345 million award is primarily trial-cost funding and reimbursement—not unrestricted cash or automatic enterprise value.
A 20× price would be
$11 per share, or approximately
$2.66 billion on the current basic share count. A 50× price would be
$27.50, or approximately
$6.65 billion. Twenty times is conceivable only as an unusually successful post-data, multi-bidder platform transaction; it is not a realistic present-day base case. Fifty times would be extremely difficult to justify before late-stage validation, commercialization visibility or multiple independently valuable programs.
Delaware law does not require either multiple. Qualifying dissenting shareholders may seek appraisal of “fair value,” but there is no statutory minimum premium, patent-value multiplier or requirement that an acquirer pay replacement value for the IP. Delaware’s appraisal statute also excludes value arising solely from the merger itself. Price is primarily determined by risk-adjusted cash flows, comparables, bargaining leverage and competitive bidding.
6. Goodwin’s significance
I would assign the Goodwin connection near-zero evidentiary weight.
Vaxart publicly identified Goodwin and Thompson Hine as its advisers in the proxy contest, while Olshan represented the dissident group. Goodwin has a dedicated shareholder-activism and takeover-defense practice, making it an entirely conventional choice for this assignment.
Goodwin has also represented companies being acquired by Sanofi—including Blueprint Medicines and Vicebio—and represented Dren Bio in a Sanofi asset acquisition. That shows Goodwin is a leading life-sciences M&A firm familiar with Sanofi transactions, but in those examples it represented Sanofi’s counterparty, not evidence of a special role as Sanofi’s hidden acquisition counsel.
Overall conclusion: Sanofi is well positioned to acquire Vaxart eventually, but the existing agreement gives Sanofi unusually strong reasons to wait. The strongest public explanation is a staged strategic option with active data access—not an acquisition already negotiated and awaiting announcement.
